<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00378105</url>
  </required_header>
  <id_info>
    <org_study_id>06-150</org_study_id>
    <nct_id>NCT00378105</nct_id>
  </id_info>
  <brief_title>Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma</brief_title>
  <official_title>An Open-Label Phase I/II Study of the Safety and Efficacy of Bortezomib, Lenalidomide and Dexamethasone Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and efficacy of the bortezomib,
      lenalidomide and dexamethasone combination in patients with newly diagnosed multiple myeloma.
      We are looking for the highest dose of the combination that can be given safely and see how
      well it works as a combination in newly diagnosed patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  The safe dose of dexamethasone is already known. The dose of bortezomib and lenalidomide
           will be increased during the study until the best and safest amount (or dose) is
           identified. The participant's dose of the study drugs will depend on when they enter the
           study.

        -  In this study each cycle will be 21 days and participants will begin the study
           medication in the clinic on Cycle 1 Day 1. Lenalidomide (capsules) will be taken daily
           for the first 2 weeks only (Day 1-14). Dexamethasone (tablets) will be taken on Day 1,
           2, 4, 5, 8, 9, 11 and 12. Bortezomib will be given intravenously in the outpatient
           treatment clinic on Day 1, 4, 8 and 11. The third week is a rest period and no study
           medication will be given.

        -  During the course of the study treatment, tests and procedures will be performed at
           designated time periods. This includes; medical history updates, physical/neurological
           examinations, skeletal survey (x-rays or scan), blood samples, optional bone marrow
           aspiration/tissue biopsy, urine samples, 12-lead ECG, and MRI/CT scan (if needed).

        -  It is expected that study participants will receive study treatment for 8 cycles (168
           days). If the participant completes the first 8 cycles of the study, has stable or
           responding disease and has not experienced bad side effects, they will be allowed to
           continue treatment on a maintenance schedule, detailed in the protocol, at the study
           doctor's discretion.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate of the Drug Combination in This Patient Populations.</measure>
    <time_frame>Full response assessment was conducted at the end of cycle 8 (average of168 days) and after cycle 4 (84 days) for patients proceeding to transplant.</time_frame>
    <description>Overall Response (OR) was defined as partial response (PR) or better. Response was assessed according to European Group for Blood and Marrow Transplant criteria, modified to include nCR and VGPR, from the International Uniform Response Criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimated 18-month Progression Free Survival (PFS) Rate</measure>
    <time_frame>PFS rate at 18 months</time_frame>
    <description>PD from European Bone Marrow Transplant (EBMT) Response Criteria Required one or more:
&gt;25% increased in the level of serum monoclonal paraprotein, which must also be an absolute increase of at least 5 g/L and confirmed on a repeat investigation, or &gt;25% increased in 24-hour urinary light chain excretion (must also be an absolute increase of at least 200 mg/24 h and confirmed on a repeat investigation), or &gt;25% increased in plasma cells in a bone marrow aspirate or biopsy (must also be an absolute increase of at least 10%) Definite increase in the size of existing lytic bone lesions or soft tissue plasmacytomas.
Development of new bone lesions or soft tissue plasmacytomas (not including compression fracture).
Development of hypercalcemia (corrected serum calcium &gt;11.5 mg/dL or 2.8 mmol/L not attributable to any other cause).
PFS was measured from treatment initiation to progression or death, censored at the date patients were last known to be alive and disease free</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Who Remained in Response for More Than 18 Months</measure>
    <time_frame>Response rate at 18 months</time_frame>
    <description>Duration of response was measured from first response to progression or death, censored at the date patients were last known to be alive and disease free for patients who had not progressed or died.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated 18-month Overall Survival Rate</measure>
    <time_frame>Survival rate at 18 months</time_frame>
    <description>Overall survival was measured from treatment initiation to death, censored at the date patients were last known to be alive for those who had not died.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>lenalidomide, dexamethasone, bortezomib combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this study each cycle will be 21 days and participants will begin the study medication in the clinic on Cycle 1 Day 1. Lenalidomide (capsules) will be taken daily for the first 2 weeks only (Day 1-14). Dexamethasone (tablets) will be taken on Day 1, 2, 4, 5, 8, 9, 11 and 12. Bortezomib will be given intravenously in the outpatient treatment clinic on Day 1, 4, 8 and 11. The third week is a rest period and no study medication will be given.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Intravenously on days 1, 4, 8 and 11 of a 21 day cycle for a minimum of 8 cycles (dosage will vary depending upon when the participant enters the trial)</description>
    <arm_group_label>lenalidomide, dexamethasone, bortezomib combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Taken orally twice a day for 2 weeks (days 1-14) of each 21-day cycle for a minimum of 8 cycles (dosage will vary depending upon when participant enters trial).</description>
    <arm_group_label>lenalidomide, dexamethasone, bortezomib combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>Taken orally on days 1,2,4,5,8,9,11 of a 21-day cycle for a minimum of 8 cycles.</description>
    <arm_group_label>lenalidomide, dexamethasone, bortezomib combination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with multiple myeloma based on standard diagnostic criteria or by the new
             International Myeloma Foundation 2003 Diagnostic Criteria

          -  Must not have been previously treated with any prior systemic therapy for the
             treatment of multiple myeloma

          -  Negative serum or urine pregnancy test

          -  Age 18 years or older

          -  Karnofsky performance status of greater or equal to 60

        Exclusion Criteria:

          -  Greater or equal to Grade 2 peripheral neuropathy on clinical examination within 14
             days before enrollment

          -  Renal insufficiency (serum creatinine &gt;2.5 mg/dL)

          -  Evidence of mucosal or internal bleeding and/or platelet refractory

          -  ANC (absolute neutrophil count)&lt; 1000 cells/mm3

          -  Hemoglobin &lt; 8.0 g/dL

          -  AST (aspartate aminotransferase) or ALT (alanine aminotransferase) greater than or
             equal to 2 x ULN (upper limit of normal)

          -  Concomitant therapy medications that include corticosteroids

          -  Myocardial infarction within 6 months prior to enrollment according to NYHA (New York
             Heart Association) Class III or IV heart failure, uncontrolled angina, severe
             uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute
             ischemia or active conduction system abnormalities

          -  Clinically relevant active infection or serious co-morbid medical conditions

          -  Prior malignancy except adequately treated basal cell or squamous cell skin cancer, in
             situ cervical, breast or prostate cancer

          -  Pregnant or breast-feeding

          -  Serious medical or psychiatric illness likely to interfere with participation in study

          -  Uncontrolled diabetes mellitus

          -  Hypersensitivity to acyclovir or similar anti-viral drug

          -  POEMS syndrome

          -  Known HIV infection

          -  Known active hepatitis B or C viral infection

          -  Known intolerance to steroid therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Richardson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2006</study_first_submitted>
  <study_first_submitted_qc>September 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2006</study_first_posted>
  <results_first_submitted>October 15, 2013</results_first_submitted>
  <results_first_submitted_qc>July 31, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 19, 2014</results_first_posted>
  <last_update_submitted>January 19, 2017</last_update_submitted>
  <last_update_submitted_qc>January 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Paul G. Richardson, MD</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>newly diagnosed multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 68 patients were enrolled in the United States. For the phase I part, this study enrolled 33 eligible patients between Sep13, 2006 and Aug16, 2007. For the phase II part, this study enrolled 35 eligible patients between Aug 20, 2007 and Feb18, 2008.</recruitment_details>
      <pre_assignment_details>Participants were screened over a two-week period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Phase 1 Population</title>
          <description>Four levels of dose were evaluated and a standard 3+3 dose escalation schema was used to determine the MTD and additional patients were evaluated on the MTD level.
Level 1 1 mg/m2/IV bortezomib daily Days 1,4, 8 and 11 40 mg PO dexamethasone daily Days 1, 2, 4, 5, 8, 9, 11, 12 and 15 mg/PO/day lenalidomide daily Days 1-14 followed by 7-day rest every 21 days
Level 2 1.3 mg/m2/IV bortezomib daily Days 1,4, 8 and 11 40 mg PO dexamethasone daily Days 1, 2, 4, 5, 8, 9, 11, 12 and 15 mg/PO/day lenalidomide daily Days 1-14 followed by 7-day rest every 21 days
Level 3 1.3 mg/m2/IV bortezomib daily Days 1,4, 8 and 11 40 mg PO dexamethasone daily Days 1, 2, 4, 5, 8, 9, 11, 12 and 20 mg/PO/day lenalidomide daily Days 1-14 followed by 7-day rest every 21 days
Level 4 1.3 mg/m2/IV bortezomib daily Days 1,4, 8 and 11 40 mg PO dexamethasone daily Days 1, 2, 4, 5, 8, 9, 11, 12 and 25 mg/PO/day lenalidomide daily Days 1-14 followed by 7-day rest every 21 days</description>
        </group>
        <group group_id="P2">
          <title>Phase 2 Pupulation</title>
          <description>Each subject received the maximum planned dose of 1.3 mg/m2/IV bortezomib daily Days 1, 4, 8 and 11 followed by a 10-day rest period, 20 mg PO dexamethasone single daily oral dose Days 1, 2, 4, 5, 8, 9, 11, 12 and25 mg/PO/QD (every day)lenalidomide daily Days 1-14 followed by 7-day rest every 21 days x 4 cycles and then at 10 mg/day on the same schedule for cycles 5 â€“ 8. Each cycle of treatment consisted of 21 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31">Out of 33 enrolled, two patients went off study before start of therapy.</participants>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Going to transplant</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive disease</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>remain on study</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Going non-protocol therapy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>necessity to increase lenalidomide dose</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The numbers excluded 2 patients who went off study prior to start of therapy (phase I part).</population>
      <group_list>
        <group group_id="B1">
          <title>Phase 1 Population</title>
        </group>
        <group group_id="B2">
          <title>Phase 2 Population</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
            <count group_id="B2" value="35"/>
            <count group_id="B3" value="66"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" lower_limit="36" upper_limit="73"/>
                    <measurement group_id="B2" value="59" lower_limit="22" upper_limit="86"/>
                    <measurement group_id="B3" value="58" lower_limit="22" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Objective Response Rate of the Drug Combination in This Patient Populations.</title>
        <description>Overall Response (OR) was defined as partial response (PR) or better. Response was assessed according to European Group for Blood and Marrow Transplant criteria, modified to include nCR and VGPR, from the International Uniform Response Criteria.</description>
        <time_frame>Full response assessment was conducted at the end of cycle 8 (average of168 days) and after cycle 4 (84 days) for patients proceeding to transplant.</time_frame>
        <population>The numbers excluded 2 patients who went off study prior to start of therapy</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 Population</title>
          </group>
          <group group_id="O2">
            <title>Phase II Population</title>
          </group>
          <group group_id="O3">
            <title>Total</title>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate of the Drug Combination in This Patient Populations.</title>
          <description>Overall Response (OR) was defined as partial response (PR) or better. Response was assessed according to European Group for Blood and Marrow Transplant criteria, modified to include nCR and VGPR, from the International Uniform Response Criteria.</description>
          <population>The numbers excluded 2 patients who went off study prior to start of therapy</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="91" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="92" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="96" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated 18-month Progression Free Survival (PFS) Rate</title>
        <description>PD from European Bone Marrow Transplant (EBMT) Response Criteria Required one or more:
&gt;25% increased in the level of serum monoclonal paraprotein, which must also be an absolute increase of at least 5 g/L and confirmed on a repeat investigation, or &gt;25% increased in 24-hour urinary light chain excretion (must also be an absolute increase of at least 200 mg/24 h and confirmed on a repeat investigation), or &gt;25% increased in plasma cells in a bone marrow aspirate or biopsy (must also be an absolute increase of at least 10%) Definite increase in the size of existing lytic bone lesions or soft tissue plasmacytomas.
Development of new bone lesions or soft tissue plasmacytomas (not including compression fracture).
Development of hypercalcemia (corrected serum calcium &gt;11.5 mg/dL or 2.8 mmol/L not attributable to any other cause).
PFS was measured from treatment initiation to progression or death, censored at the date patients were last known to be alive and disease free</description>
        <time_frame>PFS rate at 18 months</time_frame>
        <population>This numbers excluded 2 patients who went off study prior to start of therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>All Patients</title>
          </group>
        </group_list>
        <measure>
          <title>Estimated 18-month Progression Free Survival (PFS) Rate</title>
          <description>PD from European Bone Marrow Transplant (EBMT) Response Criteria Required one or more:
&gt;25% increased in the level of serum monoclonal paraprotein, which must also be an absolute increase of at least 5 g/L and confirmed on a repeat investigation, or &gt;25% increased in 24-hour urinary light chain excretion (must also be an absolute increase of at least 200 mg/24 h and confirmed on a repeat investigation), or &gt;25% increased in plasma cells in a bone marrow aspirate or biopsy (must also be an absolute increase of at least 10%) Definite increase in the size of existing lytic bone lesions or soft tissue plasmacytomas.
Development of new bone lesions or soft tissue plasmacytomas (not including compression fracture).
Development of hypercalcemia (corrected serum calcium &gt;11.5 mg/dL or 2.8 mmol/L not attributable to any other cause).
PFS was measured from treatment initiation to progression or death, censored at the date patients were last known to be alive and disease free</description>
          <population>This numbers excluded 2 patients who went off study prior to start of therapy.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75" lower_limit="63" upper_limit="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Who Remained in Response for More Than 18 Months</title>
        <description>Duration of response was measured from first response to progression or death, censored at the date patients were last known to be alive and disease free for patients who had not progressed or died.</description>
        <time_frame>Response rate at 18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Patients</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Who Remained in Response for More Than 18 Months</title>
          <description>Duration of response was measured from first response to progression or death, censored at the date patients were last known to be alive and disease free for patients who had not progressed or died.</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68" lower_limit="55" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated 18-month Overall Survival Rate</title>
        <description>Overall survival was measured from treatment initiation to death, censored at the date patients were last known to be alive for those who had not died.</description>
        <time_frame>Survival rate at 18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Patients</title>
          </group>
        </group_list>
        <measure>
          <title>Estimated 18-month Overall Survival Rate</title>
          <description>Overall survival was measured from treatment initiation to death, censored at the date patients were last known to be alive for those who had not died.</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="88" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Safety was assessed every cycle during the therapy.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>All Patients</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Altered QTc interval</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Altered Hearing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred Vision</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Extremity Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Elevated alanine transaminase</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Elevated Creatinine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sensory Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Neuropathic pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Motor Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Altered Mental Status</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary/ Upper Respiratory Event</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash/ desquamation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis/thrombus/embolism</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Stomach Hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral Edema</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Altered hearing</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>cushingoid appearance</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred Vision</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>dry eye</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>bloating</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>gastritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Other Constitutional Event</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>head and neck edema</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Genital and trunk edema</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>chills</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>weight gain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Elevated Alanine Transaminase</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>anorexia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>metabolic lab disorder</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Pain</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>joint pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>bone pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>neck pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sensory Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Neuropathic Pain</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Extremity pain</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Motor Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>tremor</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>cognitive disturbance</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>depression</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Altered mental status</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>personality change</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>confusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>urinary frequency</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pulmonary/upper respiratory event</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pruritis/itching</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>sweating</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>flushing</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>hypotension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Richardson</name_or_title>
      <organization>Dana-Farber Cancer Institute</organization>
      <phone>617-632-2104</phone>
      <email>Paul_Richardson@dfci.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

